Novartis AG (NVS) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Novartis Ag.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.057 Good morning and good afternoon and welcome to the Novartis Q2 2025 Results Release Conference 00:00:05.057 -- 00:00:09.523 Call and Live Webcast. Please note that during the presentation, all participants will 00:00:09.523 -- 00:00:12.487 be in a listen-only mode and the conference is being recorded. 00:00:12.487 -- 00:00:17.233 After the presentation, there'll be an opportunity to ask questions by pressing star 00:00:17.233 -- 00:00:20.397 1 and 1 at any time during the conference. 00:00:20.397 -- 00:00:24.820 Please limit yourself to one question and return to the queue for any follow-ups. 00:00:24.820 -- 00:00:29.046 A recording of the conference call, including the Q&A session, will be available on our 00:00:29.046 -- 00:00:33.492 website shortly after the call ends. With that, I would like to hand over to Ms. 00:00:33.492 -- 00:00:35.976 Sloane Simpson, Head of Investor Relations. 00:00:35.976 -- 00:00:38.019 Please go ahead, Madam. 00:00:38.019 -- 00:00:43.948 Thank you, Sharon. Good morning and good afternoon, everyone, and welcome to our Q2 2025 00:00:43.948 -- 00:00:49.095 earnings call. The information presented today contains forward-looking statements that 00:00:49.095 -- 00:00:53.373 involve known and unknown risks, uncertainties, and other factors. 00:00:53.373 -- 00:00:58.000 These may cause actual results to be materially different from any future results, performance, 00:00:58.000 -- 00:01:01.625 or achievements expressed or implied by such statements. 00:01:01.625 -- 00:01:06.872 For a description of some of these factors, please refer to Form 20F and its most recent 00:01:06.872 -- 00:01:12.380 quarterly results on Form 6K that respectively were filed with and furnished to the U.S. 00:01:12.380 -- 00:01:16.940 S...